Thromboxane biosynthesis

Thromboxane biosynthesis refers to the enzymatic process by which thromboxanes, primarily thromboxane A2 (TXA2), are produced from arachidonic acid in platelets and other cells. This process involves several key enzymes, most notably cyclooxygenase (COX)-1 and thromboxane synthase. The pathway begins with the release of arachidonic acid from membrane phospholipids, which is then converted by COX enzymes to prostaglandin H2 (PGH2). PGH2 is subsequently transformed into TXA2 by thromboxane synthase[1][3][7]. TXA2 is a potent mediator that promotes platelet aggregation and vasoconstriction, playing a central role in hemostasis and thrombosis[3][5][7]. Dysregulation or excessive production of TXA2 has been implicated in cardiovascular diseases such as myocardial infarction, stroke, unstable angina, and inflammatory conditions[4][7].

Other names

Thromboxane synthesisTXA2 biosynthesisPlatelet thromboxane production

Irreversible inhibition of COX enzyme activity; inhibition of thromboxane synthase; antagonism at the thromboxane receptor[5].